Managers / Q3 2021 · view latest →
Lisanti Capital Growth, LLC
CIK 0001424467 · 777 THIRD AVENUE, 14TH FLOOR, NEW YORK, NY, 10017 · 332-262-3053
Summary
Lisanti Capital Growth, LLC reported $678M in U.S.-listed holdings across 129 positions for Q3 2021.
Its largest position, SPT, represents 2.7% of the portfolio.
Compared with Q2 2021, the fund opened 44 new positions and exited 45.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 89.7% · $608M
- Other · 9.7% · $66M
- ADR · 0.6% · $4M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| BIOHAVEN PHARMACTL HLDG CO L | NEW | +85.3K | 85.3K | +$12M | $12M |
| PZZAPAPA JOHNS INTL INC | NEW | +79.1K | 79.1K | +$10M | $10M |
| RPDRAPID7 INC | NEW | +85.6K | 85.6K | +$10M | $10M |
| PAYCOR HCM INC | NEW | +243.6K | 243.6K | +$9M | $9M |
| BLD*TOPBUILD CORP | NEW | +41.1K | 41.1K | +$8M | $8M |
| MXLMAXLINEAR INC | NEW | +143.7K | 143.7K | +$7M | $7M |
| SYNASYNAPTICS INC | NEW | +38.9K | 38.9K | +$7M | $7M |
| INSPINSPIRE MED SYS INC | NEW | +29.7K | 29.7K | +$7M | $7M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2021
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $397M | 103 | May 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $422M | 110 | Feb 9, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $409M | 105 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $361M | 106 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $336M | 108 | Apr 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $416M | 111 | Feb 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $395M | 116 | Nov 4, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $416M | 115 | Aug 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $410M | 117 | May 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $424M | 124 | Feb 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $633M | 117 | Nov 3, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $721M | 135 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $717M | 108 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $732M | 122 | Feb 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $748M | 110 | Nov 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $736M | 100 | Aug 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $890M | 112 | May 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $691M | 116 | Feb 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $678M | 129 | Nov 3, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $808M | 130 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $779M | 122 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $723M | 127 | Feb 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $540M | 110 | Nov 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $491M | 117 | Aug 10, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $303M | 112 | May 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $377M | 113 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $307M | 97 | Nov 6, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $308M | 98 | Aug 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $282M | 113 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $248M | 99 | Feb 8, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.